Comparative Pharmacology
Head-to-head clinical analysis: DYCLOPRO versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLOPRO versus MECLOFENAMATE SODIUM.
DYCLOPRO vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
50 mg intravenously every 8 hours
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID